可溶性LRIG2是2型糖尿病的一种潜在生物标志物。

Soluble LRIG2 is a potential biomarker for type 2 diabetes mellitus.

作者信息

Kim Ji Min, Joung Kyong Hye, Lee Jun Choul, Choung Sorim, Kang Seon Mee, Kim Hyun Jin, Ku Bon Jeong

机构信息

Department of Endocrinology, Chungnam National University Sejong Hospital, Sejong, Republic of Korea.

Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea.

出版信息

Ann Transl Med. 2021 Nov;9(21):1612. doi: 10.21037/atm-21-3272.

DOI:10.21037/atm-21-3272

PMID:34926656

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8640903/

Abstract

BACKGROUND

Early diagnosis and treatment of type 2 diabetes can delay the onset of microvascular and macrovascular complications. Therefore, the identification of a novel biomarker for diagnosing diabetes is necessary. In the present study, the role of serum soluble leucine-rich repeats and immunoglobulin like domains 2 (sLRIG2) was investigated as a diagnostic biomarker of type 2 diabetes.

METHODS

A total of 240 subjects with newly diagnosed type 2 diabetes (n=80), prediabetes (n=80), or normal glucose tolerance (NGT; n=80) were included in this study. The fasting serum sLRIG2 level was measured using a quantitative sandwich enzyme immunoassay technique with an enzyme-linked immunosorbent assay (ELISA). Serum sLRIG2 levels were compared among the three groups, and the associations of serum sLRIG2 levels with clinical variables were investigated.

RESULTS

Serum sLRIG2 levels were significantly higher in subjects with type 2 diabetes (16.7±8.0 ng/mL) than in subjects without diabetes (NGT group: 12.3±5.3 ng/mL, P<0.001; prediabetes group: 13.2±5.8 ng/mL, P=0.002). Glycosylated hemoglobin (HbA1c: r=0.378, P<0.001) and blood glucose (fasting: r=0.421, P<0.001; 2-hour postprandial: r=0.433, P<0.001) correlated more strongly with sLRIG2 than any other clinical variables.

CONCLUSIONS

The serum sLRIG2 levels correlated with glucose parameters; thus, sLRIG2 might be a novel diagnostic biomarker for type 2 diabetes.

摘要

背景

2型糖尿病的早期诊断和治疗可延缓微血管和大血管并发症的发生。因此，有必要鉴定一种用于诊断糖尿病的新型生物标志物。在本研究中，对血清可溶性富含亮氨酸重复序列和免疫球蛋白样结构域2（sLRIG2）作为2型糖尿病诊断生物标志物的作用进行了研究。

方法

本研究共纳入240名新诊断的2型糖尿病患者（n = 80）、糖尿病前期患者（n = 80）或糖耐量正常（NGT；n = 80）的受试者。采用定量夹心酶免疫分析技术和酶联免疫吸附测定（ELISA）法测定空腹血清sLRIG2水平。比较三组之间的血清sLRIG2水平，并研究血清sLRIG2水平与临床变量之间的关联。

结果

2型糖尿病患者的血清sLRIG2水平（16.7±8.0 ng/mL）显著高于无糖尿病患者（NGT组：12.3±5.3 ng/mL，P<0.001；糖尿病前期组：13.2±5.8 ng/mL，P = 0.002）。糖化血红蛋白（HbA1c：r = 0.378，P<0.001）和血糖（空腹：r = 0.421，P<0.001；餐后2小时：r = 0.433，P<0.001）与sLRIG2的相关性比任何其他临床变量都更强。